Anti-GM-CSF Antibody

1/1
Price:
Size:
Number:

Anti-GM-CSF Antibody (Rabbit Polyclonal antibody) General Information

Product name
Anti-GM-CSF Antibody
Validated applications
WB,ELISA
Species reactivity
Reacts with: Human
Specificity
Human GM-CSF
Immunogen
Recombinant Human GM-CSF / CSF2 protein (Catalog#10015-H07H)
Preparation
Produced in rabbits immunized with purified, recombinant Human GM-CSF / CSF2 (rh GM-CSF / CSF2; Catalog#10015-H07H; NP_000749.2; Ala18-Glu144). GM-CSF / CSF2 specific IgG was purified by Human GM-CSF / CSF2 affinity chromatography.
Source
Polyclonal Rabbit IgG
Purification
Protein A & Antigen Affinity
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Anti-GM-CSF Antibody (Rabbit Polyclonal antibody) Validated Applications

Application Dilution
WB 1:500-1:2000
ELISA 1:5000-1:10000
Please Note: Optimal concentrations/dilutions should be determined by the end user.

Anti-GM-CSF Antibody (Rabbit Polyclonal antibody) Images

Anti-GM-CSF rabbit polyclonal antibody at 1:500 dilution

Lane A: U937 Whole Cell Lysate

Lane B: 293T Whole Cell Lysate

Lane C: THP-1 Whole Cell Lysate

Lane D: Jurkat Whole Cell Lysate

Lysates/proteins at 20 μg per lane.

Secondary

Goat Anti-Rabbit IgG H&L (Dylight800) at 1/10000 dilution.

Developed using the Odyssey technique.

Performed under reducing conditions.

Predicted band size:16 kDa

Observed band size:18 kDa

Anti-GM-CSF Antibody: Alternative Names

Anti-CSF2 Antibody; Anti-GM-CSF Antibody; Anti-GMCSF Antibody

GM-CSF Background Information

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.
Full Name
colony stimulating factor 2 (granulocyte-macrophage)
References
  • Robertson SA. (2007) GM-CSF regulation of embryo development and pregnancy. Cytokine Growth Factor Rev. 18(3-4): 287-98.
  • Waller EK. (2007) The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist. 12 Suppl 2: 22-6.
  • Clive KS, et al. (2010) Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines. 9(5): 519-25.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait